openPR Logo
Press release

Investigation announced for Long-Term Investors in shares of MacroGenics, Inc. (NASDAQ: MGNX)

06-14-2021 09:55 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in MacroGenics, Inc. (NASDAQ: MGNX) shares.

An investigation on behalf of current long term investors in MacroGenics, Inc. (NASDAQ: MGNX) shares.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of MacroGenics, Inc.

Investors who are current long term investors in MacroGenics, Inc. (NASDAQ: MGNX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: MGNX stocks follows a lawsuit filed against MacroGenics, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: MGNX stocks, concerns whether certain MacroGenics directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the District of Maryland the plaintiff alleges that, the defendants concealed material information and/or failed to disclose that the Company had conducted the progression-free survival (“PFS”) and first interim overall survival (“OS”) analyses for the SOPHIA trial by no later than October 10, 2018, that the October 2018 PFS analysis showed a 0.9 month improvement in PFS, and that the October 2018 OS interim analysis did not produce a statistically significant result and the interim OS Kaplan-Meier curves (a non-parametric statistic used to estimate the survival function from lifetime data) crossed in several spots (thereby violating the constant hazard assumption) and separated late.

Those who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in shares of MacroGenics, Inc. (NASDAQ: MGNX) here

News-ID: 2305003 • Views:

More Releases from Shareholders Foundation

Biohaven Ltd. (NYSE: BHVN) Investor Alert: Deadline in Lawsuit on September 12, 2025
Biohaven Ltd. (NYSE: BHVN) Investor Alert: Deadline in Lawsuit on September 12, …
A deadline is coming up on September 12, 2025in the lawsuit filed for certain investors of Biohaven Ltd. (NYSE: BHVN) over alleged securities laws violations by Biohaven Ltd. Investors who purchased shares of Biohaven Ltd. (NYSE: BHVN) have certain options and there are strict and short deadlines running. Deadline: September 12, 2025. NYSE: BHVN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to the
Investigation announced for Long-Term Investors in shares of West Pharmaceutical Services, Inc. (NYSE: WST) over potential Wrongdoing
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc.. Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed
Investigation announced for Long-Term Investors in Open Lending Corporation (NASDAQ: LPRO) over potential Wrongdoing
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation. Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings, Inc. (NYSE: BBAI)
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced. Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm

All 5 Releases


More Releases for MacroGenics

Lawsuit filed for Investors who lost money with shares of MacroGenics, Inc. (NAS …
An investor, who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX), filed a lawsuit over alleged violations of Federal Securities Laws by MacroGenics, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX) have certain options and for certain investors are short and strict deadlines running. Deadline: September 24, 2024. NASDAQ: MGNX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
Investigation announced for Investors who lost money with shares of MacroGenics, …
An investigation was announced for investors of MacroGenics, Inc. (NASDAQ: MGNX) shares over potential securities laws violations by MacroGenics, Inc. Investors who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by MacroGenics, Inc. regarding its business, its prospects and its operations were materially
Type 1 Diabetes Market May See a Big Move | DiaVacs, XOMA Corp., Biodel, Macroge …
A Latest intelligence report published by AMA Research with title "Type 1 Diabetes Market Insights, Forecast to 2030" provides latest updates and strategic steps taken by competition along with growth estimates of market size. The Type 1 Diabetes Market report gives clear visions how the research and estimates are derived through primary and secondary sources considering expert opinion, patent analysis, latest market development activity and other influencing factors. Free Sample
Lawsuit filed for Investors in shares of MacroGenics, Inc. (NASDAQ: MGNX)
An investor, who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX), filed a lawsuit over alleged violations of Federal Securities Laws by MacroGenics, Inc.. Investors who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX) have certain options and for certain investors are short and strict deadlines running. Deadline: November 12, 2019. NASDAQ: MGNX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Rockvillem MD based MacroGenics, Inc., a biopharmaceutical
Ewing Sarcoma Therapeutics - Pipeline Analysis Celgene, Novartis, Pfizer, MacroG …
Ewing sarcoma pipeline comprises approximately 29 drug candidates in different stages of development. Ewing sarcoma is a condition in which formation of cancer or tumor takes place in bones and soft tissues. The symptoms associated with Ewing sarcoma include pain as well as swelling in the chest, back, legs, pelvis and arms, lumps in arms, bone fracture, weight loss, loss of appetite, fatigue, malaise, etc. Download free report Sample at: https://www.psmarketresearch.com/market-analysis/ewing-sarcoma-therapeutics-pipeline-analysis/report-sample *Major companies
Macrogenics - Cancer Drugs Clinical Pipeline Insight
“Macrogenics - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Macrogenics. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “11” cancer drugs in clinical pipeline and majority of them are in phase-I. The report includes all the relevant information with respect to development of cancer drugs in